Why the study?
Does supplementation with intravenous unfractionated heparin during PCI prevent ischemic and thrombotic complications in patients with non-ST segment elevation acute coronary syndromes treated with fondaparinux?
Does supplementation with intravenous unfractionated heparin during PCI prevent ischemic and thrombotic complications in patients with non-ST segment elevation acute coronary syndromes treated with fondaparinux?
Supplementation with unfractionated heparin during PCI in patients with NSTE-ACS treated with fondaparinux is associated with low rates of ischemic and hemorrhagic complications and eliminates catheter-related thrombosis.
Answers are grounded in this paper and cite their sources.
Associated with low ischemic and bleeding rates in this cohort; leaves open need for randomized confirmation in NSTE-ACS on fondaparinux.
Fondaparinux is an agent that has a well-established safety and efficacy profile in the treatment of non-ST segment elevation acute coronary syndromes. When used alone, however, it is associated with a higher incidence of thrombotic complications during invasive coronary procedures, requiring the supplementation of an anti-IIa agent. This study aimed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) in patients with non-ST segment elevation acute coronary syndromes that were previously treated with fondaparinux. This was a prospective, controlled registry, enrolling 127 consecutive patients submitted to an early invasive stratification during treatment with fondaparinux with the supplementation of intravenous unfractionated heparin at a dose of 85 U/kg at the time of PCI. The composite primary endpoint rate, including death, acute myocardial infarction, stroke, stent thrombosis, or emergency myocardial revascularisation was 3.2%. The cumulative incidence of major bleeding and vascular complications was 3.2%. There were no cases of guide catheter thrombosis or abrupt vessel closure. PCI in patients with acute coronary syndromes receiving fondaparinux was associated with a low rate of major adverse cardiovascular ischaemic events and severe haemorrhagic complications. Supplementation with unfractionated heparin during the invasive procedures eliminated the risk of catheter-related thrombosis. Fondaparinux em Intervenção Coronária Percutânea no Tratamento da Síndrome Coronária Aguda Considerado um fármaco com adequado perfil de eficácia e segurança no tratamento da síndrome coronária aguda sem supradesnivelamento do segmento ST, o fonda parinux, utilizado de forma isolada, associase a maior ocorrência de complicações trombóticas durante a realização de procedimentos coronários invasivos, requerendo a adição de agente com atividade anti-IIa. Este estudo teve como objetivo avaliar a eficácia e a segurança da intervenção coronária percutânea (ICP) em pacientes admitidos com diagnóstico de síndrome coronária aguda sem supradesnivelamento do segmento ST, previamente tratados com fondaparinux. Registro prospectivo, controlado, envolvendo 127 pacientes consecutivos submetidos a estratificação invasiva precoce na vigência de fondaparinux, com suplementação de heparina não fracionada intravenosa na dose de 85 U/kg no momento da ICP. A taxa do desfecho primário, composto por morte, infarto agudo do miocárdio, acidente vascular encefálico, trombose de stent ou revascularização miocárdica de urgência, foi de 3,2%. A incidência acumulada de sangramento grave e complicações vasculares foi de 3,2%. Não houve casos de trombose do cateterguia ou oclusão abrupta do vaso. A ICP em pacientes com síndrome coronária aguda em uso de fondaparinux associase a baixas taxas de eventos cardiovasculares adversos isquêmicos e de complicações hemorrágicas graves. A suplementação com heparina não fracionada durante o procedimento invasivo elimina o risco de trombose do cateter.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: